1.Research on clinical value of soluble triggering receptor expressed on myeloid cells-1 in the treatment and therapeutic effect evaluation of patients with an exacerbation of chronic obstructive pulmonary disease
Rao LIU ; Faping ZHONG ; Wenjun PEI ; Tianli WANG ; Zegang YANG ; Yeqiang ZOU
Journal of Chinese Physician 2015;17(9):1331-1334
Objective To investigate the clinical value of serum soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) in the treatment and therapeutic effect evaluation of patients with an exacerbation of chronic obstructive pulmonary disease.Methods The levels of serum sTREM-1,procalcitonin (PCT) and C-reactive protein (CRP) were determined by enzyme-linked immunosorbent assay (ELISA) in 49 exacerbation of chronic obstructive pulmonary disease (COPD) subjects [acute exacerbation of chronic obstructive pulmonary disease (AECOPD) group],49 stable COPD subjects(sCOPD group) after treatment and 49 healthy volunteers as healthy control group.The levels of sTREM-1,PCT and CRP in different groups were compared and the relationship between the level of sTREM-1 in AECOPD and sCOPD groups,and PCT,and CRP was analyzed,respectively.Results The content of sTREM-1,PCT and CRP between different groups had significant difference(P <0.05).The level of sTREM-1 in both AECOPD and sCOPD groups was significantly positive correlated with PCT (P < 0.05) and negative correlated with CRP (P > 0.05).Conclusions For guiding the treatment and curative effect evaluation of patients with AECOPD,sTREM-1 has important clinical reference value.
2.Research progress on targeted therapy of breast cancer with low expression of HER2
Jun ZHU ; Meijin HUANG ; Yuan LI ; Zegang LIU ; Xin XUN ; Hong CHEN
Journal of International Oncology 2023;50(4):236-240
Breast cancer has become the malignant tumor with the highest incidence rate among women, of which human epidermal growth factor receptor 2 (HER2) positive breast cancer accounts for about 15%-20%. With the development of anti HER2 targeted drugs, the survival and prognosis of HER2 positive breast cancer has significantly benefited. About 45%-55% of breast cancer patients have low HER2 expression, and these patients usually do not receive anti HER2 treatment. However, there is a significant difference between the biological behavior and prognosis of breast cancer with low HER2 expression and breast cancer with zero HER2 expression. It is helpful to differentiate and adopt corresponding treatment strategies to improve the prognosis of patients. At present, there have been many advances in targeted therapy of breast cancer with low HER2 expression, which provides a useful reference for precision treatment of breast cancer with low HER2 expression.
3. Analysis of 8 274 cases of new coronavirus nucleic acid detection and co-infection in Wuhan
Ming WANG ; Qing WU ; Wanzhou XU ; Bin QIAO ; Jingwei WANG ; Hongyun ZHENG ; Shupeng JIANG ; Junchi MEI ; Zegang WU ; Yayun DENG ; Fangyuan ZHOU ; Wei WU ; Yan ZHANG ; Zhihua LYU ; Jingtao HUANG ; Xiaoqian GUO ; Zhen CHEN ; Lina FENG ; Zunen XIA ; Di LI ; Tiangang LIU ; Pingan ZHANG ; Yongqing TONG ; Zhiliang XU ; Yan LI
Chinese Journal of Laboratory Medicine 2020;43(0):E016-E016
Objective:
To investigate the positive rate for 2019-nCoV tests and co-infections in Wuhan district.
Methods:
A total of 8 274 cases in Wuhan were enrolled in this cross-sectional study during January 20 to February 9, 2020, and were tested for 2019-nCoV using fluorescence quantitative PCR. Both respiratory tract samples (nasopharynx, oropharynx, sputum and alveolar lavage fluid) and non-respiratory tract samples (urine, feces, anal swabs, blood and conjunctival sac swabs) were collected. If both orf1ab and N genes are positive, they are classified as nucleic acid test positive group; if both orf1ab and N genes are negative, they are classified as negative group; if single gene target is positive, they are classified as suspicious group. Individuals were divided into male group and female group according to sex. At the same time, 316 patients were tested for 13 respiratory pathogens by multiplex PCR.
Results:
Among the 8 274 subjects, 2 745 (33.2%) were 2019-nCoV infected; 5 277 (63.8%) subjects showed negative results in the 2019-nCoV nucleic acid test; and 252 cases (3.05%) was not definitive (inconclusive result). The age of cases with COVID-19 patients and inconclusive cases was significantly higher than that of cases without 2019-nCoV infection (40 vs 56,